Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience.
Elderly patients
Induction chemotherapy
Methotrexate
Primary central nervous system lymphoma
Rituximab
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
14
03
2023
accepted:
22
06
2023
revised:
21
06
2023
medline:
11
8
2023
pubmed:
2
7
2023
entrez:
1
7
2023
Statut:
ppublish
Résumé
The prognosis of primary central nervous system lymphoma (PCNSL) in the elderly remains poor. We aimed to evaluate the outcome of rituximab, methotrexate, procarbazine, and vincristine (RMPV) chemotherapy in elderly patients with new-onset PCNSL. Twenty-eight patients aged ≥ 70 years treated for PCNSL between 2010 and 2020 were examined retrospectively. Nineteen patients received RMPV and nine did not qualify. Patients received five to seven cycles of RMPV plus response-adapted whole-brain radiotherapy (WBRT) and cytarabine. Ten of the 19 patients who received RMPV (52.6%) completed the induction, but only four patients (21.1%) completed RMPV chemotherapy, WBRT 23.4 Gy, and cytarabine. Median progression-free survival (PFS) and overall survival (OS) in the RMPV group was 54.4 and 85.0 months, respectively. Both PFS and OS were significantly longer in patients who received RMPV chemotherapy than in those who did not, and in patients who started but did not complete RMPV than in those who did not receive RMPV. Patients who received incomplete RMPV tended to have a favorable prognosis. Initial treatment with RMPV chemotherapy was effective in elderly patients with PCNSL. Adjusting the number of courses of RMPV may improve the prognosis of elderly patients with PCNSL, but further verification is necessary.
Identifiants
pubmed: 37393325
doi: 10.1007/s12185-023-03632-9
pii: 10.1007/s12185-023-03632-9
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Methotrexate
YL5FZ2Y5U1
Vincristine
5J49Q6B70F
Cytarabine
04079A1RDZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-339Informations de copyright
© 2023. Japanese Society of Hematology.
Références
van der Meulen M, et al. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015. Leukemia. 2017;31(8):1822–5.
doi: 10.1038/leu.2017.128
pubmed: 28450731
Houillier C, et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 2020;94(10):e1027–39.
doi: 10.1212/WNL.0000000000008900
pubmed: 31907289
pmcid: 7238921
Eloranta S, et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000–2013. Eur J Haematol. 2018;100(1):61–8.
doi: 10.1111/ejh.12980
pubmed: 28983970
Kasenda B, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)–a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305–13.
doi: 10.1093/annonc/mdv076
pubmed: 25701456
pmcid: 4735103
Mendez JS, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687–94.
doi: 10.1093/neuonc/nox187
pubmed: 29036697
van der Meulen M, et al. Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands. Haematologica. 2021;106(2):597–600.
doi: 10.3324/haematol.2020.247536
pubmed: 32241841
Morris PG, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9.
doi: 10.1200/JCO.2013.50.4910
pubmed: 24101038
pmcid: 5569679
Shah GD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730–5.
doi: 10.1200/JCO.2007.12.5062
pubmed: 17947720
Abrey LE, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–43.
doi: 10.1200/JCO.2005.13.524
pubmed: 15955902
Abrey LE, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–5.
doi: 10.1200/JCO.2006.08.2941
pubmed: 17116938
Laack NN, et al. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96–73-51. Int J Radiat Oncol Biol Phys. 2006;65(5):1429–39.
doi: 10.1016/j.ijrobp.2006.03.061
pubmed: 16863926
Zhu JJ, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11(2):211–5.
doi: 10.1215/15228517-2008-067
pubmed: 18757775
pmcid: 2718993
Roth P, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012;79(9):890–6.
doi: 10.1212/WNL.0b013e318266fcb2
pubmed: 22895585
Schmitt AM, et al. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis. Hematol Oncol. 2019;37(5):548–57.
doi: 10.1002/hon.2666
pubmed: 31418878
Fritsch K, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22(9):2080–5.
doi: 10.1093/annonc/mdq712
pubmed: 21303800
Holdhoff M, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83(3):235–9.
doi: 10.1212/WNL.0000000000000593
pubmed: 24928128
pmcid: 4117362
Houillier C, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol. 2017;133(2):315–20.
doi: 10.1007/s11060-017-2435-7
pubmed: 28432587
Makino K, et al. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience. Int J Clin Oncol. 2015;20(1):29–34.
doi: 10.1007/s10147-014-0692-4
pubmed: 24722885
Schorb E, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020;4(14):3378–81.
doi: 10.1182/bloodadvances.2020002064
pubmed: 32722778
pmcid: 7391148
Bairey O, Siegal T. The possible role of maintenance treatment for primary central nervous system lymphoma. Blood Rev. 2018;32(5):378–86.
doi: 10.1016/j.blre.2018.03.003
pubmed: 29551465
Vu K, et al. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019;186(1):180–3.
doi: 10.1111/bjh.15787
pubmed: 30714128
pmcid: 8776513
Grommes C, et al. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol. 2019;21(3):306–13.
doi: 10.1093/neuonc/noy193
pubmed: 30423172
Narita, Y., et al., Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma. Neuro Oncol, 2020.